Literature DB >> 22342674

Breaking through a roadblock in prostate cancer research: an update on human model systems.

R Toivanen1, R A Taylor, D W Pook, S J Ellem, G P Risbridger.   

Abstract

Prostate cancer is a prevalent disease that affects the aging male population. Whilst there have been significant advances of our biological understanding of the disease, clinical translation of promising agents continues to lag behind. In part, this is due to a paucity of relevant experimental and pre-clinical models required to further develop effective prevention and therapeutic strategies. Genetically modified cell lines fail to entirely represent the genetic and molecular diversity of primary human specimens, particularly from localised disease. Furthermore, primary prostate cancer tissues are extremely difficult to grow in the laboratory and virtually all human models, whether they grow as xenografts in immune-deficient animals or as cell cultures, are genetically modified by the investigator or derived from patients with advanced metastatic disease. In this review, we discuss the latest advances and improvements to current methods of xenografting human primary prostate cancer, and their potential application to translational research.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22342674     DOI: 10.1016/j.jsbmb.2012.01.005

Source DB:  PubMed          Journal:  J Steroid Biochem Mol Biol        ISSN: 0960-0760            Impact factor:   4.292


  15 in total

Review 1.  Patient-Derived Prostate Cancer: from Basic Science to the Clinic.

Authors:  Gail P Risbridger; Renea A Taylor
Journal:  Horm Cancer       Date:  2016-05-13       Impact factor: 3.869

Review 2.  Development of patient-derived xenograft models of prostate cancer for maintaining tumor heterogeneity.

Authors:  Changhong Shi; Xue Chen; Dengxu Tan
Journal:  Transl Androl Urol       Date:  2019-10

3.  To target or not to target the enemy within localized prostate cancer.

Authors:  Gail Risbridger; Renea Taylor
Journal:  Cell Cycle       Date:  2013-09-23       Impact factor: 4.534

4.  Castrate-tolerant cells: what are the implications for the treatment of localized prostate cancer?

Authors:  Gail Risbridger; Renea Taylor
Journal:  Asian J Androl       Date:  2013-07-22       Impact factor: 3.285

Review 5.  Ex vivo culture of human prostate tissue and drug development.

Authors:  Margaret M Centenera; Ganesh V Raj; Karen E Knudsen; Wayne D Tilley; Lisa M Butler
Journal:  Nat Rev Urol       Date:  2013-06-11       Impact factor: 14.432

6.  Identification of Novel Response and Predictive Biomarkers to Hsp90 Inhibitors Through Proteomic Profiling of Patient-derived Prostate Tumor Explants.

Authors:  Elizabeth V Nguyen; Margaret M Centenera; Max Moldovan; Rajdeep Das; Swati Irani; Andrew D Vincent; Howard Chan; Lisa G Horvath; David J Lynn; Roger J Daly; Lisa M Butler
Journal:  Mol Cell Proteomics       Date:  2018-04-09       Impact factor: 5.911

7.  Modeling human prostate cancer progression in vitro.

Authors:  Teresa T Liu; Jonathan A Ewald; Emily A Ricke; Robert Bell; Colin Collins; William A Ricke
Journal:  Carcinogenesis       Date:  2019-07-20       Impact factor: 4.944

8.  Establishing prostate cancer patient derived xenografts: lessons learned from older studies.

Authors:  Pamela J Russell; Peter Russell; Christina Rudduck; Brian W C Tse; Elizabeth D Williams; Derek Raghavan
Journal:  Prostate       Date:  2015-01-05       Impact factor: 4.104

9.  Optimization and comprehensive characterization of a faithful tissue culture model of the benign and malignant human prostate.

Authors:  Sophia Lisette Maund; Rosalie Nolley; Donna Mae Peehl
Journal:  Lab Invest       Date:  2013-12-02       Impact factor: 5.662

10.  A preclinical xenograft model of prostate cancer using human tumors.

Authors:  Mitchell G Lawrence; Renea A Taylor; Roxanne Toivanen; John Pedersen; Sam Norden; David W Pook; Mark Frydenberg; Melissa M Papargiris; Birunthi Niranjan; Michelle G Richards; Hong Wang; Anne T Collins; Norman J Maitland; Gail P Risbridger
Journal:  Nat Protoc       Date:  2013-04-04       Impact factor: 13.491

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.